
Lilly goes cellular for $34m
And conveniently, Celltrans blazes a trail for cell therapies in diabetes.

The waxing and waning of the speedy approval
As the FDA cools on the accelerated pathway, could biopharma’s annual approval count take a hit?
And conveniently, Celltrans blazes a trail for cell therapies in diabetes.
As the FDA cools on the accelerated pathway, could biopharma’s annual approval count take a hit?